StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Moderna's operating cash flow for the twelve months ending Jun 30, 2026 was -$1.07B. For fiscal 2025 it was -$1.87B. The highest annual figure on record is $13.62B in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.87B–
FY2024Dec 31, 2024-$3.00B–
FY2023Dec 31, 2023-$3.12B-162.6%
FY2022Dec 31, 2022$4.98B-63.4%
FY2021Dec 31, 2021$13.62B+571.9%
FY2020Dec 31, 2020$2.03B–
FY2019Dec 31, 2019-$459.00M–
FY2018Dec 31, 2018-$330.87M–
FY2017Dec 31, 2017-$331.48M-596.7%
FY2016Dec 31, 2016$66.73M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$526.00M–
Q1 FY2026Mar 31, 2026-$630.00M–
Q4 FY2025Dec 31, 2025$930.00M+12.7%
Q3 FY2025Sep 30, 2025-$847.00M–
Q2 FY2025Jun 30, 2025-$919.00M–
Q1 FY2025Mar 31, 2025-$1.04B–
Q4 FY2024Dec 31, 2024$825.00M+32.6%
Q3 FY2024Sep 30, 2024-$1.57B–
Q2 FY2024Jun 30, 2024-$1.27B–
Q1 FY2024Mar 31, 2024-$989.00M–
Q4 FY2023Dec 31, 2023$622.00M-62.6%
Q3 FY2023Sep 30, 2023-$1.60B-734.9%
Q2 FY2023Jun 30, 2023-$915.00M-401.0%
Q1 FY2023Mar 31, 2023-$1.23B-144.3%
Q4 FY2022Dec 31, 2022$1.66B-49.8%
Q3 FY2022Sep 30, 2022$252.00M-92.3%
Q2 FY2022Jun 30, 2022$304.00M-92.5%
Q1 FY2022Mar 31, 2022$2.76B-7.0%
Q4 FY2021Dec 31, 2021$3.31B+161.9%
Q3 FY2021Sep 30, 2021$3.28B+266.9%
Q2 FY2021Jun 30, 2021$4.06B–
Q1 FY2021Mar 31, 2021$2.97B–
Q4 FY2020Dec 31, 2020$1.26B–
Q3 FY2020Sep 30, 2020$893.00M–
Q2 FY2020Jun 30, 2020-$24.00M–
Q1 FY2020Mar 31, 2020-$106.00M–
Q4 FY2019Dec 31, 2019-$99.05M–
Q3 FY2019Sep 30, 2019-$107.09M–
Q2 FY2019Jun 30, 2019-$108.59M–
Q1 FY2019Mar 31, 2019-$144.27M–
Q4 FY2018Dec 31, 2018-$91.02M–
Q3 FY2018Sep 30, 2018-$80.21M–
Q2 FY2018Jun 30, 2018-$48.25M–
Q1 FY2018Mar 31, 2018-$111.39M–

More Moderna figures

See a number that looks wrong?